NO20053956L - Brystkreftresistentsprotein (BCRP)-inhibitor - Google Patents
Brystkreftresistentsprotein (BCRP)-inhibitorInfo
- Publication number
- NO20053956L NO20053956L NO20053956A NO20053956A NO20053956L NO 20053956 L NO20053956 L NO 20053956L NO 20053956 A NO20053956 A NO 20053956A NO 20053956 A NO20053956 A NO 20053956A NO 20053956 L NO20053956 L NO 20053956L
- Authority
- NO
- Norway
- Prior art keywords
- salt
- glycopyranosyl
- alkyl
- alkoxy
- hydrogen
- Prior art date
Links
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 title abstract 4
- 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- -1 hydroxy, nitro, amino, acetylamino Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- VFOKYTYWXOYPOX-RVDMUPIBSA-N (z)-2,3-diphenylprop-2-enenitrile Chemical class C=1C=CC=CC=1C(/C#N)=C/C1=CC=CC=C1 VFOKYTYWXOYPOX-RVDMUPIBSA-N 0.000 abstract 1
- QAQHAGQKCVWGNC-NTEUORMPSA-N (z)-2-(3,4-dimethoxyphenyl)-3-(4-hydroxyphenyl)prop-2-enenitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(\C#N)=C\C1=CC=C(O)C=C1 QAQHAGQKCVWGNC-NTEUORMPSA-N 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- 229910004727 OSO3H Inorganic materials 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 229940121649 protein inhibitor Drugs 0.000 abstract 1
- 239000012268 protein inhibitor Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003026856 | 2003-02-04 | ||
| PCT/JP2004/001067 WO2004069243A1 (ja) | 2003-02-04 | 2004-02-03 | 乳癌耐性蛋白（ｂｃｒｐ）阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053956D0 NO20053956D0 (no) | 2005-08-25 |
| NO20053956L true NO20053956L (no) | 2005-10-26 |
Family
ID=32844154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053956A NO20053956L (no) | 2003-02-04 | 2005-08-25 | Brystkreftresistentsprotein (BCRP)-inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7371773B2 (pl) |
| EP (1) | EP1591117A4 (pl) |
| JP (1) | JPWO2004069243A1 (pl) |
| KR (1) | KR20050096954A (pl) |
| CN (1) | CN1744892A (pl) |
| AU (1) | AU2004210259B2 (pl) |
| BR (1) | BRPI0407264A (pl) |
| CA (1) | CA2515174A1 (pl) |
| EA (1) | EA009048B1 (pl) |
| IL (1) | IL169913A0 (pl) |
| MX (1) | MXPA05008298A (pl) |
| NO (1) | NO20053956L (pl) |
| PL (1) | PL378073A1 (pl) |
| TW (1) | TW200505433A (pl) |
| WO (1) | WO2004069243A1 (pl) |
| ZA (1) | ZA200505988B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002226225B2 (en) * | 2001-01-18 | 2008-03-20 | Dermavant Sciences GmbH | Novel 1,2-diphenylethene derivatives for treatment of immune diseases |
| EP1591117A4 (en) | 2003-02-04 | 2006-04-26 | Yakult Honsha Kk | BCRP (BREAST CANCER RESISTANCE PROTEIN) INHIBITOR |
| US7282339B2 (en) * | 2003-09-17 | 2007-10-16 | Invitrogen Corporation | Competitive immunoassay |
| NZ562143A (en) | 2005-03-30 | 2010-12-24 | Yakult Honsha Kk | Dimethoxyphenyl-acrylonitrile derivatives and uses thereof in the treatment of cancer |
| KR20100100826A (ko) | 2007-12-03 | 2010-09-15 | 가부시끼가이샤 야구르트혼샤 | Ａｂｃｇ2 저해제 |
| US8802702B2 (en) * | 2009-01-15 | 2014-08-12 | The General Hospital Corporation | Compounds for reducing drug resistance and uses thereof |
| FR2941456B1 (fr) * | 2009-01-26 | 2011-03-04 | Univ Claude Bernard Lyon | Nouveaux composes de type azapeptide ou azapeptidomimetrique inhibiteurs de bcrp et/ou p-gp. |
| US9168297B2 (en) | 2010-06-23 | 2015-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (NRG-1) |
| CN105503652B (zh) * | 2015-12-30 | 2017-12-05 | 延边大学 | 含氰基白藜芦醇类似物及其制备方法和用途 |
| US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| JPWO2021215517A1 (pl) | 2020-04-22 | 2021-10-28 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3151148A (en) | 1964-09-29 | Cyano stilbene hypocholesterolemic | ||
| JP2799101B2 (ja) * | 1992-03-04 | 1998-09-17 | シャープ株式会社 | 有機非線形光学材料 |
| GB9207437D0 (en) * | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
| JP3144662B2 (ja) * | 1993-08-05 | 2001-03-12 | 森永乳業株式会社 | スチルベン誘導体とスチルベン同族体誘導体及びそれらの用途 |
| JP3180127B2 (ja) * | 1993-03-10 | 2001-06-25 | 森永乳業株式会社 | スチルベン誘導体とスチルベン同族体誘導体及びそれらの用途 |
| AU669279B2 (en) | 1993-03-10 | 1996-05-30 | Morinaga Milk Industry Company Limited | Stilbene derivative and stilbene analog derivative, and use thereof |
| TW325458B (en) * | 1993-09-08 | 1998-01-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer |
| US5731353A (en) * | 1993-09-08 | 1998-03-24 | Ajinomoto Co., Inc. | Stilbene derivatives and pharmaceutical compositions containing them |
| US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| TW334418B (en) | 1995-03-07 | 1998-06-21 | Ajinomoto Kk | Stilbene derivatives and pharmaceutical compositions |
| JP3163391B2 (ja) * | 1995-03-07 | 2001-05-08 | 味の素株式会社 | スチルベン誘導体及びそれを含有する制癌剤 |
| JP4642226B2 (ja) * | 1998-02-06 | 2011-03-02 | デ モントフォート ユニヴァーシティ | ヒドロキシル化により活性化されたプロドラッグ |
| WO1999051246A1 (en) * | 1998-04-03 | 1999-10-14 | Ajinomoto Co., Inc. | Antitumor agents |
| CA2360022A1 (en) * | 1999-01-08 | 2000-07-13 | Bristol-Myers Squibb Company | Prokaryotic system designed to monitor protease activity |
| EP1591117A4 (en) | 2003-02-04 | 2006-04-26 | Yakult Honsha Kk | BCRP (BREAST CANCER RESISTANCE PROTEIN) INHIBITOR |
-
2004
- 2004-02-03 EP EP04707629A patent/EP1591117A4/en not_active Withdrawn
- 2004-02-03 PL PL378073A patent/PL378073A1/pl not_active Application Discontinuation
- 2004-02-03 AU AU2004210259A patent/AU2004210259B2/en not_active Ceased
- 2004-02-03 CN CNA2004800032473A patent/CN1744892A/zh active Pending
- 2004-02-03 KR KR1020057013822A patent/KR20050096954A/ko not_active Ceased
- 2004-02-03 US US10/544,064 patent/US7371773B2/en not_active Expired - Fee Related
- 2004-02-03 WO PCT/JP2004/001067 patent/WO2004069243A1/ja not_active Ceased
- 2004-02-03 JP JP2005504836A patent/JPWO2004069243A1/ja active Pending
- 2004-02-03 EA EA200501247A patent/EA009048B1/ru unknown
- 2004-02-03 MX MXPA05008298A patent/MXPA05008298A/es active IP Right Grant
- 2004-02-03 BR BR0407264-2A patent/BRPI0407264A/pt not_active IP Right Cessation
- 2004-02-03 CA CA002515174A patent/CA2515174A1/en not_active Abandoned
- 2004-02-04 TW TW093102500A patent/TW200505433A/zh unknown
-
2005
- 2005-07-26 IL IL169913A patent/IL169913A0/en unknown
- 2005-07-26 ZA ZA200505988A patent/ZA200505988B/xx unknown
- 2005-08-25 NO NO20053956A patent/NO20053956L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004069243A1 (ja) | 2004-08-19 |
| AU2004210259B2 (en) | 2008-12-11 |
| MXPA05008298A (es) | 2005-09-20 |
| NO20053956D0 (no) | 2005-08-25 |
| US20060128636A1 (en) | 2006-06-15 |
| ZA200505988B (en) | 2006-12-27 |
| TW200505433A (en) | 2005-02-16 |
| BRPI0407264A (pt) | 2006-01-31 |
| PL378073A1 (pl) | 2006-02-20 |
| JPWO2004069243A1 (ja) | 2006-05-25 |
| CN1744892A (zh) | 2006-03-08 |
| AU2004210259A1 (en) | 2004-08-19 |
| EP1591117A4 (en) | 2006-04-26 |
| EA009048B1 (ru) | 2007-10-26 |
| KR20050096954A (ko) | 2005-10-06 |
| IL169913A0 (en) | 2007-07-04 |
| CA2515174A1 (en) | 2004-08-19 |
| EP1591117A1 (en) | 2005-11-02 |
| EA200501247A1 (ru) | 2006-02-24 |
| US7371773B2 (en) | 2008-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200300776A1 (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| ATE302775T1 (de) | Carbolinderivate | |
| BR0309427A (pt) | Novo uso de um composto (2z)-2-ciano-3-hidroxi-n-[4-(trifluorometil)fenil]-2-hep tano-6-inamida ou 5-(3-butinil)-n-[4-(trifluorometil)fenil]-4-isoxazoleca rbo-amida | |
| DE60237145D1 (de) | Chinazolinderivate | |
| DE69618231D1 (de) | TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER | |
| EA200200208A1 (ru) | Синергитическая композиция | |
| CY1106801T1 (el) | Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα | |
| DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| UY27175A1 (es) | Nueva sal succinato de o-desmetil- venlafaxina | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| DE60317198D1 (de) | Proteinkinaseinhibitoren | |
| DE60331187D1 (de) | Kinaseinhibitoren | |
| BR0316502A (pt) | Compostos quìmicos | |
| DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
| NO20053956L (no) | Brystkreftresistentsprotein (BCRP)-inhibitor | |
| ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| BR0008763A (pt) | Derivados de piridopiranoazepinas, a preparação dos mesmos e a respectiva aplicação em terapêutica | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| ATE332903T1 (de) | Kondensierte pyridoindolderivate | |
| YU59298A (sh) | Postupak za dobijanje fenil heterociklusa korisnih kao inhibitora cox-2 | |
| SE0302546D0 (sv) | New compounds | |
| EA200400475A1 (ru) | Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли | |
| DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
| ATE296827T1 (de) | Heteropolycyclische inhibitoren | |
| ATE333457T1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |